[1] W.J. Evans, J.E. Morley, J. Argilés, C. Bales, V. Baracos, et al., Cachexia: A new definition, Clinical Nutrition, 27 (2008) 793-799, https://doi.org/10.1016/j.clnu.2008.06.013.
[2] C.M.M. Prado, J.R. Lieffers, L.J. McCargar, T. Reiman, M.B. Sawyer, et al., Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, The Lancet Oncology, 9 (2008) 629-635, https://doi.org/10.1016/S1470-2045(08)70153-0.
[3] T.S. Solheim, B.J.A. Laird, T.R. Balstad, G.B. Stene, A. Bye, et al., A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer, Journal of Cachexia, Sarcopenia and Muscle, 8 (2017) 778-788, 10.1002/jcsm.12201.
[4] D.P. Kotler, Cachexia, Annals of Internal Medicine, 133 (2000) 622-634, 10.7326/0003-4819-133-8-200010170-00015.
[5] J.S. Temel, A.P. Abernethy, D.C. Currow, J. Friend, E.M. Duus, et al., Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials, The Lancet Oncology, 17 (2016) 519-531, https://doi.org/10.1016/S1470-2045(15)00558-6.
[6] A. Vigano, N. Donaldson, I.J. Higginson, E. Bruera, S. Mahmud, et al., Quality of life and survival prediction in terminal cancer patients, Cancer, 101 (2004) 1090-1098, 10.1002/cncr.20472.
[7] P.F. Cosper, L.A. Leinwand, Cancer Causes Cardiac Atrophy and Autophagy in a Sexually Dimorphic Manner, Cancer Research, 71 (2011) 1710, 10.1158/0008-5472.CAN-10-3145.
[8] J. Springer, A. Tschirner, A. Haghikia, S. von Haehling, H. Lal, et al., Prevention of liver cancer cachexia-induced cardiac wasting and heart failure, European Heart Journal, 35 (2013) 932-941, 10.1093/eurheartj/eht302.
[9] Kenneth C.H. Fearon, David J. Glass, Denis C. Guttridge, Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways, Cell Metabolism, 16 (2012) 153-166, 10.1016/j.cmet.2012.06.011.
[10] E. Garfield, Citation analysis as a tool in journal evaluation, Science (New York, N.Y.), 178 (1972) 471-479, 10.1126/science.178.4060.471.
[11] K. Fearon, J. Arends, V. Baracos, Understanding the mechanisms and treatment options in cancer cachexia, Nature Reviews Clinical Oncology, 10 (2013) 90-99, 10.1038/nrclinonc.2012.209.
[12] M.B. Synnestvedt, C. Chen, J.H. Holmes, CiteSpace II: visualization and knowledge discovery in bibliographic databases, AMIA Annu Symp Proc, 2005 (2005) 724-728,
[13] N.J. van Eck, L. Waltman, CitNetExplorer: A new software tool for analyzing and visualizing citation networks, Journal of Informetrics, 8 (2014) 802-823, https://doi.org/10.1016/j.joi.2014.07.006.
[14] N.J. van Eck, L. Waltman, Software survey: VOSviewer, a computer program for bibliometric mapping, Scientometrics, 84 (2010) 523-538, 10.1007/s11192-009-0146-3.
[15] E. Bruera, K. Macmillan, N. Kuehn, J. Hanson, R.N. MacDonald, A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer, Cancer, 66 (1990) 1279-1282, 10.1002/1097-0142(19900915)66:6<1279::aid-cncr2820660630>3.0.co;2-r.
[16] C.L. Loprinzi, N.M. Ellison, D.J. Schaid, J.E. Krook, L.M. Athmann, et al., Controlled Trial of Megestrol Acetate for the Treatment of Cancer Anorexia and Cachexia, JNCI: Journal of the National Cancer Institute, 82 (1990) 1127-1132, 10.1093/jnci/82.13.1127.
[17] G. Strassmann, M. Fong, J.S. Kenney, C.O. Jacob, Evidence for the involvement of interleukin 6 in experimental cancer cachexia, The Journal of Clinical Investigation, 89 (1992) 1681-1684, 10.1172/JCI115767.
[18] M.J. Tisdale, Cachexia in cancer patients, Nature Reviews Cancer, 2 (2002) 862-871, 10.1038/nrc927.
[19] K.C.H. Fearon, M.F. von Meyenfeldt, A.G.W. Moses, R. van Geenen, A. Roy, et al., Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial, Gut, 52 (2003) 1479, 10.1136/gut.52.10.1479.
[20] A. Inui, Cancer Anorexia-Cachexia Syndrome: Current Issues in Research and Management, CA: A Cancer Journal for Clinicians, 52 (2002) 72-91, 10.3322/canjclin.52.2.72.
[21] A.W.G. Moses, C. Slater, T. Preston, M.D. Barber, K.C.H. Fearon, Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids, British Journal of Cancer, 90 (2004) 996-1002, 10.1038/sj.bjc.6601620.
[22] K.C. Fearon, A.C. Voss, D.S. Hustead, Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis, The American Journal of Clinical Nutrition, 83 (2006) 1345-1350, 10.1093/ajcn/83.6.1345.
[23] K.C.H. Fearon, Cancer cachexia: Developing multimodal therapy for a multidimensional problem, European Journal of Cancer, 44 (2008) 1124-1132, https://doi.org/10.1016/j.ejca.2008.02.033.
[24] M.J. Tisdale, Mechanisms of Cancer Cachexia, Physiological Reviews, 89 (2009) 381-410, 10.1152/physrev.00016.2008.
[25] M. Mourtzakis, C.M.M. Prado, J.R. Lieffers, T. Reiman, L.J. McCargar, et al., A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care, Applied Physiology, Nutrition, and Metabolism, 33 (2008) 997-1006, 10.1139/H08-075.
[26] D.C. McMillan, Systemic inflammation, nutritional status and survival in patients with cancer, Current Opinion in Clinical Nutrition & Metabolic Care, 12 (2009) 223-226, 10.1097/MCO.0b013e32832a7902.
[27] C.M.M. Prado, V.E. Baracos, L.J. McCargar, T. Reiman, M. Mourtzakis, et al., Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment, Clinical Cancer Research, 15 (2009) 2920, 10.1158/1078-0432.CCR-08-2242.
[28] K. Fearon, F. Strasser, S.D. Anker, I. Bosaeus, E. Bruera, et al., Definition and classification of cancer cachexia: an international consensus, The Lancet Oncology, 12 (2011) 489-495, https://doi.org/10.1016/S1470-2045(10)70218-7.
[29] B.H.L. Tan, L.A. Birdsell, L. Martin, V.E. Baracos, K.C.H. Fearon, Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer, Clinical Cancer Research, 15 (2009) 6973, 10.1158/1078-0432.CCR-09-1525.
[30] J. Arends, P. Bachmann, V. Baracos, N. Barthelemy, H. Bertz, et al., ESPEN guidelines on nutrition in cancer patients, Clinical Nutrition, 36 (2017) 11-48, https://doi.org/10.1016/j.clnu.2016.07.015.
[31] M. Bossola, F. Pacelli, A. Tortorelli, G.B. Doglietto, Cancer Cachexia: It’s Time for More Clinical Trials, Annals of Surgical Oncology, 14 (2007) 276-285, 10.1245/s10434-006-9179-5.
[32] C. Deans, S.J. Wigmore, Systemic inflammation, cachexia and prognosis in patients with cancer, Current Opinion in Clinical Nutrition & Metabolic Care, 8 (2005) 265-269, 10.1097/01.mco.0000165004.93707.88.
[33] L. Martin, L. Birdsell, N. MacDonald, T. Reiman, M.T. Clandinin, et al., Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index, Journal of Clinical Oncology, 31 (2013) 1539-1547, 10.1200/jco.2012.45.2722.
[34] B.S. van der Meij, C.P. Schoonbeek, E.F. Smit, M. Muscaritoli, P.A. van Leeuwen, et al., Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks, Br J Nutr, 109 (2013) 2231-2239, 10.1017/S0007114512004527.
[35] J. Feliu, M. González-Barón, A. Berrocal, A. Artal, A. Ordóñez, et al., Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study, American journal of clinical oncology, 15 (1992) 436-440, 10.1097/00000421-199210000-00008.
[36] S. Miller, L. McNutt, M.-A. McCann, N. McCorry, Use of Corticosteroids for Anorexia in Palliative Medicine: A Systematic Review, Journal of Palliative Medicine, 17 (2014) 482-485, 10.1089/jpm.2013.0324.
[37] T.W. Davis, B.S. Zweifel, J.M. Neal, D.M. Heuvelman, A.L. Abegg, et al., Inhibition of Cyclooxygenase-2 by Celecoxib Reverses Tumor-Induced Wasting, Journal of Pharmacology and Experimental Therapeutics, 308 (2004) 929, 10.1124/jpet.103.063099.
[38] C. Madeddu, M. Dessì, F. Panzone, R. Serpe, G. Antoni, et al., Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome, Clinical Nutrition, 31 (2012) 176-182, https://doi.org/10.1016/j.clnu.2011.10.005.
[39] J.-a. Chen, A. Splenser, B. Guillory, J. Luo, M. Mendiratta, et al., Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved, Journal of Cachexia, Sarcopenia and Muscle, 6 (2015) 132-143, 10.1002/jcsm.12023.
[40] J.M. Garcia, J.P. Cata, P.M. Dougherty, R.G. Smith, Ghrelin Prevents Cisplatin-Induced Mechanical Hyperalgesia and Cachexia, Endocrinology, 149 (2008) 455-460, 10.1210/en.2007-0828.
[41] F. Strasser, T.A. Lutz, M.T. Maeder, B. Thuerlimann, D. Bueche, et al., Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study, British Journal of Cancer, 98 (2008) 300-308, 10.1038/sj.bjc.6604148.
[42] R.M. Goldberg, C.L. Loprinzi, J.A. Mailliard, J.R. O'Fallon, J.E. Krook, et al., Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial, Journal of Clinical Oncology, 13 (1995) 2856-2859, 10.1200/jco.1995.13.11.2856.
[43] M. Kraft, K. Kraft, S. Gärtner, J. Mayerle, P. Simon, et al., L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial, Nutrition Journal, 11 (2012) 52, 10.1186/1475-2891-11-52.
[44] S. Busquets, M.T. Figueras, G. Fuster, V. Almendro, R. Moore-Carrasco, et al., Anticachectic Effects of Formoterol, Cancer Research, 64 (2004) 6725, 10.1158/0008-5472.CAN-04-0425.
[45] M.E. Falagas, E.I. Pitsouni, G.A. Malietzis, G. Pappas, Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses, The FASEB Journal, 22 (2008) 338-342, 10.1096/fj.07-9492LSF.